COMMUNIQUÉS West-GlobeNewswire

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
03/06/2025
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the early tender results in connection with its previously announced tender offers [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
03/06/2025
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the [...]
Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent Advancements and Potential Recombinant Spider Silk Deliveries in 2025
03/06/2025
ANN ARBOR, Mich., June 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, issues a letter to shareholders. Dear [...]
Vanqua Bio to Present at Upcoming Scientific Conferences
03/06/2025
CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio , a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its lead clinical program, VQ-101, at two upcoming [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/2025
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired [...]
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
03/06/2025
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of [...]
Conavi Medical Announces New Grant of Stock Options
03/06/2025
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“ Conavi Medical ” or the “ Company ”), announced that its board of directors (the “Board”) has approved grants of stock [...]
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
03/06/2025
Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing allo-HCT Saint-Louis, [...]
Oculis to Participate in Upcoming June Investor Conferences
03/06/2025
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Oculis to Participate in Upcoming June Investor Conferences
03/06/2025
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases
03/06/2025
Financing co-led by new investor BRM Group and existing investor Pontifax Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatment of three rare genetic skin diseases; [...]
CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
03/06/2025
Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology Lehi, June 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 3rd, 2025 – CancerVax, Inc., the developer of [...]
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
03/06/2025
Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the [...]
Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat et un prix cible de 4,00 €
03/06/2025
Communiqué de presse Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat et un prix cible de 4,00 € Dijon, France le 3 juin 2025 (07h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), [...]
Addex Convenes Annual General Meeting 2025
03/06/2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
03/06/2025
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first- [...]
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
03/06/2025
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseases Under regulatory review in the US, the EU, and China in immune [...]
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose
03/06/2025
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose Quatrième désignation de médicament orphelin pour le rilzabrutinib dans les maladies rares En cours d’ [...]
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl [...]

Pages